LXRX FY 2025 Earnings — Lexicon Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

LXRXLexicon Pharmaceuticals, Inc.

$704M

FY 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$50M+60.2% YoY

Gross Profit

$50M99.4% margin

Operating Income

-$49M-98.2% margin

Net Income

-$50M-101.1% margin

EPS (Diluted)

$-0.14

Cash Flow

Operating Cash Flow

-$68M

Free Cash Flow

-$68M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$185M

Total Liabilities

$77M

Stockholders' Equity

$108M

Cash & Equivalents

$34M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$50M	$31M	+60.2%
Gross Profit	$50M	$30M	+62.6%
Operating Income	-$49M	-$197M	+75.2%
Net Income	-$50M	-$200M	+74.9%